Salivary gland dynamic imaging combined with tomosynthesis fusion imaging for evaluating postoperative salivary gland function changes in patients with differentiated thyroid cancer undergoing initial 131I therapy Authors: Yanni Yang, Aijuan Tian, Jing Yu, Pingping Ni, Zhaoyan Zhong Published: 2026 ABSTRACT AbstractBackground131I therapy is a targeted therapy for patients with differentiated thyroid cancer (DTC) after surgery, reducing the risk of tumor recurrence and metastasis. Radioactive iodine can accumulate in the salivary glands, causing radiation damage. Dynamic imaging of the salivary glands can objectively assess the morphology and function of the salivary glands, making it a simple and non-invasive diagnostic method. The purpose of this study was to quantitatively analyze salivary gland function changes in patients with DTC undergoing postoperative 131I therapy using salivary gland dynamic imaging combined with tomographic fusion imaging.MethodsA retrospective study enrolled 49 patients with DTC who underwent total thyroidectomy and received initial 131I therapy (dose: 5.55 GBq) between May 2020 and March 2024. Salivary gland dynamic imaging was performed on the day before 131I therapy and at least 4 months post-therapy. Salivary gland dynamic imaging was performed to measure the concentration index (CI), secretion index (SI), maximum standardized uptake value (SUVmax) of bilateral salivary glands, as well as SUVmax in the temporal region. The CI, SI, and the relative SUVmax (rSUVmax) in bilateral salivary glands to the temporal region were used as evaluation indicators.ResultsThere were no statistically significant differences in the CI or SI of bilateral salivary glands before and after 131I therapy (P>0.05). The rSUVmax of parotid gland to temporal region showed a statistically significant difference before and after 131I therapy (P<0.05), whereas the rSUVmax of submandibular gland to temporal region showed no statistically significant difference (P>0.05).ConclusionsIn patients with DTC undergoing postoperative treatment, administering 131I therapy at an initial dose of 5.55 GBq with acid stimulation in the early phase can impair parotid gland function. Quantitative analysis using salivary gland dynamic imaging combined with tomographic fusion imaging enables accurate assessment of salivary gland function.Keywords: Salivary gland dynamic imaging, differentiated thyroid cancer (DTC), salivary gland function Introduction 131I therapy is the classic targeted treatment for patients with differentiated thyroid cancer (DTC) after surgery (1). It works by concentrating radioactively labeled iodine within thyroid follicular cells via sodium/iodide cotransporter (SIT1) active transport across the cell membrane. The resulting β radiation induces edema, degeneration, and necrosis in target cells, thereby eliminating residual thyroid tissue and cancer foci to reduce tumor recurrence and metastasis (2). However, sodium/iodide symporter is also present on the epithelial membranes of salivary gland ducts (3,4). Radioactive iodine similarly accumulates in salivary glands, leading to extremely high 131I concentrations—approximately 30–40 times higher than in plasma (5)—causing radiation damage to salivary glands. This manifests as xerostomia (dry mouth) and sialadenitis (salivary gland inflammation) (6,7). Salivary gland dynamic imaging can be used to assess salivary gland function by leveraging the ability of ductal epithelial cells in the salivary glands to actively uptake technetium pertechnetate (99mTcO4−) from the bloodstream and secrete it into the oral cavity via saliva (8). This method provides an objective evaluation of salivary gland morphology and function, serving as a simple, non-invasive diagnostic approach (9). Previous studies have predominantly employed semiquantitative analysis using indices such as uptake and secretion indices (10,11). This study utilized salivary gland tomographic fusion imaging to delineate the volume of interest (VOI) and obtain the maximum standardized uptake value (SUVmax), thereby evaluating salivary gland function in patients undergoing their first 131I therapy following DTC surgery. We present this article in accordance with the STROBE reporting checklist (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0911/rc). Methods Clinical data A retrospective review included 49 postoperative DTC patients who underwent their first 131I therapy at the Department of Nuclear Medicine, The Second Affiliated Hospital of Dalian Medical University between May 2020 and March 2024. Among them, 25 were male and 24 were female, aged 29 to 78 years with a median age of 48 years. The diagnoses included 45 cases of papillary carcinoma and 4 of follicular carcinoma. Salivary gland scintigraphy combined with tomographic fusion imaging was performed at baseline and at least 4 months post-treatment [median 6.3 months, interquartile range (IQR), 4.7–10.2 months] when the first lesion was detected. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Ethics Committee of The Second Affiliated Hospital of Dalian Medical University (No. KY2025-554-01), and the requirement for individual consent for this retrospective analysis was waived. Inclusion criteria Patients were over 18 years old; Patients were over 18 years old; Patients who have undergone total or near-total thyroidectomy with healed surgical wounds; Patients who have undergone total or near-total thyroidectomy with healed surgical wounds; Pathologically diagnosed with DTC postoperatively; Pathologically diagnosed with DTC postoperatively; Patients with good compliance; Patients with good compliance; Patients in good general condition with white blood cell count not less than 3.0×109/L; Patients in good general condition with white blood cell count not less than 3.0×109/L; First-time 131I therapy recipients; First-time 131I therapy recipients; Patients with complete medical documentation, including clinical records, laboratory findings, and pre- and post-treatment radionuclide imaging data of salivary gland function. Patients with complete medical documentation, including clinical records, laboratory findings, and pre- and post-treatment radionuclide imaging data of salivary gland function. Exclusion criteria History of salivary gland dysfunction symptoms such as dry mouth, salivary gland swelling/pain, taste alteration, or dysphagia prior to 131I therapy; History of salivary gland dysfunction symptoms such as dry mouth, salivary gland swelling/pain, taste alteration, or dysphagia prior to 131I therapy; History of head and neck radiotherapy; History of head and neck radiotherapy; Pregnant or lactating women; Pregnant or lactating women; Long-term use of medications affecting salivary gland function such as anticholinergic drugs during 131I therapy and subsequent follow-up periods; Long-term use of medications affecting salivary gland function such as anticholinergic drugs during 131I therapy and subsequent follow-up periods; Multiple 131I treatments during follow-up; Multiple 131I treatments during follow-up; Incomplete salivary gland function radionuclide imaging data; Incomplete salivary gland function radionuclide imaging data; Concurrent severe dysfunction of cardiac, hepatic, or renal systems; Concurrent severe dysfunction of cardiac, hepatic, or renal systems; Adverse changes in blood cell counts. Adverse changes in blood cell counts. 131I therapy All patients underwent a low-iodine diet or medication for 3 weeks and discontinued levothyroxine (levothyroxine sodium tablets) for 3 weeks to achieve a thyroid-stimulating hormone (TSH) level greater than 30 mIU/L before 131I therapy. On the day of 131I therapy, patients received a 5.55 GBq (150 mCi) dose of 131I for thyroid clearance. Concurrently, they took oral prednisone 10 mg three times daily on the treatment day. Two hours after treatment, patients administered 0.1 g of vitamin C sublingually three times daily or consumed acidic foods until one week after the completion of treatment. Patients were encouraged to drink ample water (2,000–2,500 mL each day) and maintain oral hygiene to stimulate salivary gland secretion and mitigate radiation effects on these glands. Instruments and methods Instruments The single photon emission computed tomography (SPECT) scanner was a GE Discovery NM 630 model (GE Healthcare, Chicago, IL, USA) equipped with a low-energy high-resolution collimator. The radioactivity monitor was a CRC-15R (Capintec, Florham Park, NJ, USA). Imaging agent 99mTcO4− was purchased from Beijing Atomic High-Tech Co., Ltd. (Beijing, China) Imaging method Salivary gland dynamic imaging was performed the day before 131I therapy, and more than 4 months after treatment. The patient was positioned supine on the examination table with the head slightly extended and fixed in a forward position. The probe field of view encompassed both parotid glands and submandibular glands. Settings: matrix 128×128, energy peak 140 keV, window width 20%, magnification 2.0. Images were acquired immediately after a 99mTcO4− injection via the “bullet” technique into the elbow vein [dose: 370 MBq (10 mCi)]. The total image acquisition time was 30 minutes: 1 frame was acquired every 2 seconds for 1 minute, then 9 minutes at 1 frame per minute for dynamic imaging; subsequently, 10 minutes of tomographic fusion images; followed by 10 minutes at 1 frame per minute for dynamic imaging. In the 25th minute, the patient was administered 500 mg vitamin C orally to stimulate salivary secretion. Before and after the “bullet-style” injection, the 99mTcO4− radioactivity count in the syringe was measured and the measurement time recorded, while simultaneously recording the injection time. Image evaluation Images were reviewed jointly by one attending physician and one associate chief physician from the Nuclear Medicine Department, employing visual assessment and semi-quantitative analysis. Using Xeleris post-processing software on the GE image post-processing workstation, regions of interest (ROIs) were delineated on salivary gland dynamic imaging for both parotid glands and both submandibular glands, ensuring they covered the entire parotid and submandibular glands as much as possible. Simultaneously, a frontal ROI was delineated as the background. The computer automatically generated the corresponding time-radioactivity curve (TAC) (Figure 1), and semi-quantitative analysis was performed. The concentration index (CI) was calculated as: CI = (maximum radioactive count of the gland before acid stimulation − background count)/background count. The secretion index (SI) was calculated as: SI = (maximum radioactivity count of the gland − minimum radioactivity count after acid stimulation)/maximum radioactivity count of the gland × 100%. On the head and neck tomographic fusion images (Figures 2,3), a VOI was delineated. Using computer post-processing software, the SUVmax was obtained for the bilateral parotid glands, bilateral submandibular glands, and temporal region. Then, the local SUVmax of bilateral parotid glands and bilateral submandibular glands was divided by the temporal region SUVmax to obtain relative SUVmax (rSUVmax) (Figure 4). On the salivary gland dynamic imaging, delineate the ROI of bilateral parotid glands and bilateral submandibular glands, while delineating the frontal region as the background ROI. The computer automatically generates the corresponding TAC. ROI, region of interest; TAC, time-radioactivity curve. Head and neck CT fusion imaging (bilateral parotid glands). CT, computed tomography. Head and neck CT fusion imaging (bilateral submandibular glands). CT, computed tomography. Enter height, weight, full-needle radioactivity, empty-needle radioactivity, and corresponding measurement times. Outline the VOI of bilateral parotid glands, bilateral submandibular glands, and temporal region. Using Xeleris post-processing software to obtain the SUVmax for the corresponding region. SUVmax, maximum standardized uptake value; VOI, volume of interest. Data analysis Statistical analysis was performed using the software SPSS 25.0 (IBM Corp., Armonk, NY, USA), which was released in August 2017. The analyses were conducted on a Windows 10 operating system. Normally distributed quantitative data were expressed as mean ± standard deviation, whereas non-normally distributed quantitative data were presented as median and IQR. Paired t-tests and Wilcoxon signed-rank tests were used to compare pre- and post-treatment groups. A P value less than 0.05 was considered statistically significant. Results A total of 49 patients underwent salivary gland scintigraphy before and several months after (median 6.3 months, IQR, 4.7–10.2 months) 131I therapy. Table 1 summarizes pre- and post-treatment CI, SI, and rSUVmax for bilateral parotid and submandibular glands. There were no statistically significant differences in CI or SI of bilateral salivary glands before and after treatment (P>0.05). Following 131I therapy, the rSUVmax of bilateral glands decreased. The rSUVmax in bilateral parotid glands showed a statistically significant decrease (P<0.05), whereas the rSUVmax in bilateral submandibular glands did not differ significantly (P>0.05). Table 1Differential analysis of bilateral salivary gland CI, SI, and rSUVmax before and after 131I therapySalivary glandGroup (n=49)P valueBefore 131I therapyAfter 131I therapyLeft parotid gland CI25.19±22.3722.41±17.930.509 SI50.92±10.1649.63±13.190.489 rSUVmax12.23 (10.33, 15.50)10.29 (7.78, 12.02)0.001Right parotid gland CI23.52±19.3622.82±18.370.853 SI48.00 (39.00, 56.50)48.00 (39.00, 57.50)0.356 rSUVmax12.09 (9.18, 15.28)9.99 (8.19, 13.67)0.021Left submandibular gland CI16.80 (9.32, 27.50)14.00 (9.00, 27.17)0.651 SI36.29±12.8336.08±13.690.902 rSUVmax22.55 (13.46, 33.50)20.79 (12.13, 26.65)0.052Right submandibular gland CI19.00 (8.57, 29.00)14.20 (6.91, 27.75)0.968 SI33.55±13.1736.51±12.390.080 rSUVmax23.81 (14.04, 31.80)19.73 (11.50, 30.44)0.187Data are presented as mean ± standard deviation or median (interquartile range). CI, concentrate index; rSUVmax, ratio of maximum standardized uptake volume; SI, secretion index. Differential analysis of bilateral salivary gland CI, SI, and rSUVmax before and after 131I therapy Data are presented as mean ± standard deviation or median (interquartile range). CI, concentrate index; rSUVmax, ratio of maximum standardized uptake volume; SI, secretion index. Discussion Iodine-131-related sialadenitis is a relatively common complication following radioactive iodine therapy, presenting with symptoms such as salivary gland pain, swelling, and dry mouth, which adversely affect patients’ quality of life. Previous clinical diagnostic methods, including salivary flow rate measurement (12), sialography (13), and biopsy (14), were all invasive procedures and could not simultaneously provide anatomical images and functional data of the salivary glands. In 1975, Higashi et al. first employed a gamma camera for 99mTcO4− salivary gland dynamic imaging (15). Nearly 50 years of clinical practice have demonstrated that salivary gland scintigraphy, as a non-invasive examination method, can display the location, morphology, and size of salivary glands while also observing their function and duct patency. It holds unique clinical value in diagnosing salivary gland diseases and assessing their function, serving as a safe, accurate, and convenient examination method. Previous studies evaluating salivary gland function changes in patients undergoing 131I therapy after DTC surgery typically employed a “bullet-style” injection of 99mTcO4− via the elbow vein followed by continuous dynamic acquisition, taking approximately 30 minutes. Semi-quantitative analysis was performed by delineating ROI and obtaining TAC through computer post-processing (16). Quantitative methods for salivary gland function assessment include positron emission tomography/computed tomography (PET/CT) and SPECT/CT. Zhao et al. investigated the value of gallium-68 prostate-specific membrane antigen-11 (68Ga-PSMA-11) PET/CT in evaluating salivary and lacrimal gland function. Compared with salivary gland dynamic imaging, their study demonstrated the supplementary value of 68Ga-PSMA-11 PET/CT quantitative analysis in evaluating salivary gland function beyond the semi-quantitative assessment provided by dynamic imaging (17). Shang et al. utilized xSPECT Quant combined with salivary gland dynamic imaging to evaluate the value of assessing parotid gland and residual thyroid function in patients prior to 131I therapy after DTC surgery. The results indicated that SUVmean effectively reflects the average uptake capacity of the parotid gland, demonstrating certain clinical application value (18). Unlike previous literature that mostly used dynamic salivary gland imaging or ultrasound as assessment methods, this study innovatively combines dynamic salivary gland imaging with tomographic fusion imaging, and introduces SUVmax and rSUVmax for quantitative calibration, providing a more precise and individualized assessment of salivary gland function. Salivary gland dynamic imaging is a planar SPECT imaging technique for which semi-quantitative analysis relies on the observer’s experience. Combined tomographic fusion imaging provides higher resolution for functional metabolic and anatomical images than simple planar imaging, enabling direct visualization and quantitative analysis. This study commenced with a 10-minute continuous acquisition of salivary gland dynamic images, followed by a 10-minute head and neck tomographic fusion imaging session, then another 10-minute continuous acquisition of salivary dynamic images, totaling 30 minutes. Semi-quantitative analysis was performed by delineating ROI in planar images and obtaining TAC through computer post-processing. Quantitative analysis involved delineating VOI and calculating SUVmax via computer post-processing. The results showed no significant changes in salivary gland function after initial 131I therapy in patients with DTC following surgery, as indicated by semi-quantitative analysis. Meanwhile, quantitative analysis revealed marked impairment in parotid gland function. This indicates that, compared to traditional semi-quantitative functional metrics such as CI and SI, quantitative analysis using tomographic fusion imaging combined with salivary gland dynamic imaging provides superior assessment of salivary gland function. Of note, although the between-group differences in rSUVmax reached statistical significance, the absolute reduction in SUVmax for the salivary glands was relatively modest, and the CI and SI of salivary glands remained largely preserved. These findings suggest that, in our current study, the metabolic activity of glandular parenchyma was inhibited to a certain extent; however, this suppression may not have crossed the pathophysiological threshold required to induce severe functional decompensation. The preservation of CI and SI further implies a relatively homogeneous injury pattern affecting both major gland types, or the presence of compensatory mechanisms that buffer the overall functional loss. The high sensitivity of rSUVmax renders it a promising biomarker for detecting subclinical glandular dysfunction, and the quantified change of less than 20% offers a valuable reference for establishing future interventional thresholds. Bellini et al. pointed out that in recent years, studies have increasingly focused on combining imaging indicators with patient-reported outcomes to establish more clinically meaningful assessment systems (19). The quantitative approach used in this study is a positive response to this trend. In this study, the temporal region was chosen as a reference area based on its relatively stable metabolism under physiological conditions, effectively serving as a 'background' signal within the individual. By calculating the SUV ratio between the salivary gland and the temporal region, we can maximize correction for SUV fluctuations caused by non-targeted factors such as metabolic differences, injection dosage, body weight, and scanning conditions, making salivary gland function assessments between individuals more comparable (20). The core logic of this methodology, namely the ‘target/non-target ratio’, is consistent with the classic salivary gland function assessment indicators CI and SI in nuclear medicine, and is fundamentally scientifically justified. Previous reports have established an association between radiation dose and salivary gland dysfunction (21). Parthasarathy and Crawford noted that significant side effects are rarely observed at doses below 3.7 GBq (22). One study demonstrated that a single 6 GBq dose of 131I resulted in approximately 30% loss of salivary gland parenchymal function, whereas a cumulative dose of 35 GBq led to complete glandular dysfunction (23). Maruoka et al. observed significant reductions in parotid uptake and excretion fractions in 193 patients treated with 3.3–9.5 GBq (24). Beyond radiation dose effects on salivary gland function, the early use of acidic substances following 131I therapy remains a major point of debate among researchers. Acidic substances can both enhance salivary gland uptake of radioactive iodine and stimulate salivary secretion, making the timing of their administration controversial. Some studies encourage patients to immediately consume vitamin C or sour candies after 131I administration to potentially reduce glandular damage. However, Jentzen et al. conducted meticulous dosimetric studies revealing higher absorbed doses in salivary glands following early stimulation (25-27). In our study, acidic medications or foods were administered 2 hours after a single 5.55 GBq iodine dose, potentially increasing salivary gland radiation sensitivity and leading to dysfunction. Nevertheless, submandibular gland function showed no significant impairment in our patients. The differing radiosensitivity of the two glands may stem from their distinct cellular compositions. The parotid gland consists of serous acini, the cells of which exhibit selective radiosensitivity (28), whereas the submandibular gland contains both mucous and serous cells. These mucous cells continuously secrete mucin without external stimulation, providing a protective barrier against radiation (29). Our study revealed parotid dysfunction persisting for 4 months or even longer following 131I therapy at a dose of 5.55 GBq. Solans et al. conducted a 3-year follow-up of patients receiving cumulative 131I doses ranging from 925 MBq to 18.5 GBq. They observed that salivary gland dysfunction was a transient side effect in most cases, though it could persist for extended periods or manifest later in some patients (21). Tanwar et al. observed significantly impaired uptake and secretion functions in both parotid and submandibular glands on salivary gland scintigraphy approximately 20 days after postoperative 131I therapy in patients with thyroid carcinoma (11). Malpani et al. reported marked salivary gland dysfunction at 2 months post-iodine ingestion, with parotid gland impairment being more pronounced than submandibular gland impairment (29). Bohuslavizki et al. documented mild parenchymal dysfunction after 3 months of iodine ingestion (30). Patients enrolled in this study underwent salivary gland dynamic imaging over 4 months after iodine administration. Their concentrate and secretion indices showed no significant difference compared to pre-iodine ingestion levels, with only reduced parotid rSUVmax observed. This suggests that salivary gland function may begin to recover in some patients. Assessing the extent of salivary gland impairment and recovery following 131I therapy in post-surgical DTC patients facilitates timely intervention and improves quality of life. In the current study, we evaluated salivary gland function in patients receiving relatively high doses of 131I therapy using combined salivary gland dynamic imaging and tomographic fusion imaging. Research on salivary gland function in patients treated with lower doses of 131I is lacking. Although we analyzed the changes in salivary gland function before and after treatment, we did not conduct a stratified analysis of the longitudinal changes in individual patients. The degree of change in salivary gland function can vary significantly among individuals. Exploring the potential determinants of these individual differences would help to achieve a more personalized interpretation of imaging findings and provide more accurate guidance for clinical decision-making. Additionally, several limitations merit consideration. As a retrospective study conducted at a single clinical center, there are certain limitations, and a larger-scale, multicenter, prospective study may be conducted in the future. Furthermore, the sample size of this study was small and did not subjectively assess salivary gland symptoms. Future research should combine imaging indicators with validated questionnaires and pain scales to comprehensively assess changes in salivary gland function. Conclusions This study shows that in patients receiving adjuvant 131I therapy after DTC surgery, an initial ablation dose of 5.55 GBq given early after radioactive iodine intake under acidic oral stimulation conditions can cause a significant but limited decrease in parotid gland metabolic activity, measured by rSUVmax derived from SPECT/CT fusion imaging scans. This highlights the outstanding sensitivity of quantitative functional imaging in detecting subtle metabolic changes that traditional methods find difficult to capture. At the methodological level, this study validates the value of integrating dynamic salivary gland imaging with tomosynthesis imaging as a robust, non-invasive, and reproducible objective platform for salivary function assessment, with potential for promotion in routine post-131I monitoring. In summary, this study advocates for the inclusion of quantitative imaging biomarkers in the post-treatment follow-up system for DTC patients, to enable early identification of individuals at risk of progressive salivary function injury and to promote timely prevention or treatment interventions. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. This study was approved by the Ethics Committee of The Second Affiliated Hospital of Dalian Medical University (No. KY2025-554-01), and individual consent for this retrospective analysis was waived. Footnotes Reporting Checklist: The authors have completed the STROBE reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0911/rc Funding: This work was supported by “1+X” Research Project of The Second Affiliated Hospital of Dalian Medical University (No. YXJS 2024005). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0911/coif). A.T. received research funding from “1+X” Research Project of The Second Affiliated Hospital of Dalian Medical University (No. YXJS 2024005). The other authors have no conflicts of interest to declare. Data Sharing Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0911/dss References Associated Data Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2026-0911/dss